By the Top Tier Newswire AI Desk · October 6, 2026 at 12:13 AM ET · reviewed against 8 wire stories
INSMED INC (INSM) is down -6.56% in the latest session. Our newswire has captured 8 stories on INSM across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 51/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
INSM stock fell 6.56% to $103.83 on Friday, driven by the announcement that Chief Financial Officer Sara Bonstein will step down on October 30, 2026. The leadership transition comes amid the company’s reaffirmation of its 2026 revenue guidance for BRINSUPRI and ARIKAYCE. The move reflects investor concern over the departure of a long-tenured executive and uncertainty around the company’s financial trajectory.
What Happened
Insmed (INSM) announced that CFO Sara Bonstein will leave the company on October 30, 2026, after nearly seven years in the role. She will remain in her position through the Q3 2026 earnings call scheduled for October 29. The company also reiterated its 2026 revenue guidance, projecting $1.25 billion to $1.4 billion for BRINSUPRI and $450 million to $470 million for ARIKAYCE. Despite the guidance reaffirmation, the news led to a sharp decline in INSM shares. The SEC 8-K filing on October 5 confirmed the CFO’s departure and outlined related compensatory arrangements.
What The Data Shows
The stock has fallen 12.2% over the past eight sessions, declining from $119.39 to $104.85. Recent insider transactions show 7 sales totaling $42.9 million in the last 90 days, with no insider buys recorded. On the 52-week tape, INSM printed 12 fresh 52-week lows on October 5, reflecting ongoing volatility. The company remains unprofitable with a trailing twelve-month EPS of -4.09 and a net margin of -76.9%. Its market cap stands at $24.3 billion.
What To Watch
Investors should monitor the Q3 2026 earnings call on October 29 for further details on the CFO transition and financial performance. The company’s ability to maintain its 2026 guidance amid leadership changes will be a key focus for market participants.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 8 stories · 51/100 neutral
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
17h agoMarketChameleonBULLISH 56General
Insmed Sets CFO Exit Date as It Reaffirms 2026 Revenue Guidance for BRINSUPRI and ARIKAYCE
October 5, 2026
Insmed said CFO Sara Bonstein will step down on October 30, 2026, remaining in the role through the company’s Q3 2026 results and the October 29 earnings call. Alongside the leadership change, Insmed reaffirmed full-year 2026 revenue guidance for BRINSUPRI and ARIKAYCE, keeping investors focused on commercial execution heading into the upcoming quarterly update.
18h agoInvesting.com MarketsBEARISH 38General
Insmed stock falls as CFO Sara Bonstein to step down
Insmed stock falls as CFO Sara Bonstein to step down
21h agoSeeking AlphaNEUTRAL 50General
Insmed CFO Sara Bonstein to step down, reaffirms guidance
Insmed Incorporated (INSM) said CFO Sara Bonstein will step down from the role on October 30, after nearly seven years with the company.
21h agoMarketChameleonNEUTRAL 53General
Insmed (INSM) CFO to Step Down After Nearly Seven Years as Company Reaffirms 2026 Revenue Guidance
October 5, 2026
Insmed (INSM) announced that CFO Sara Bonstein will step down on October 30, 2026, and will remain in the role through the company’s Q3 2026 results and October 29 earnings call. Alongside the leadership update, Insmed reaffirmed its full-year 2026 revenue guidance for BRINSUPRI ($1.25B–$1.40B) and ARIKAYCE ($450M–$470M).
Filed: 2026-10-05 AccNo: 0001140361-26-038529 Size: 225 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
22h agoPR NewswireNEUTRAL 50General
Insmed Announces CFO Transition
—Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership— —Company Reaffirms Full-Year 2026 Financial Guidance— —Company Announces Third-Quarter 2026 Financial Results Conference Call to Be Held on Thursday, October 29, 2026— BRIDGEWATER, N.J.,...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →